New hope for lung cancer patients: immunotherapy drug durvalumab tested after chemoradiation
NCT ID NCT06992609
First seen Nov 01, 2025
Summary
This study tests the drug durvalumab as a consolidation (follow-up) treatment for people with limited-stage small cell lung cancer whose cancer has not grown after chemoradiation. About 70 participants in Spain will receive durvalumab every 4 weeks for up to 24 months. The goal is to see how safe and effective this treatment is in a real-world setting, including patients who may not have been eligible for earlier trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGA Coruña, 15006, Spain
-
Research Site
RECRUITINGBadajoz, 06080, Spain
-
Research Site
RECRUITINGBarakaldo, 48903, Spain
-
Research Site
RECRUITINGBarcelona, 08035, Spain
-
Research Site
RECRUITINGBarcelona, 08036, Spain
-
Research Site
RECRUITINGBarcelona, 08907, Spain
-
Research Site
RECRUITINGJerez de la Frontera, 11407, Spain
-
Research Site
RECRUITINGMadrid, 28041, Spain
-
Research Site
RECRUITINGMadrid, 28046, Spain
-
Research Site
RECRUITINGMálaga, 29010, Spain
-
Research Site
RECRUITINGOviedo, 33011, Spain
-
Research Site
RECRUITINGSantander, 39008, Spain
-
Research Site
RECRUITINGSeville, 41013, Spain
-
Research Site
RECRUITINGValencia, 46026, Spain
-
Research Site
RECRUITINGZaragoza, 50009, Spain
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (an immunotherapy drug)
What this could lead to
If successful, this could confirm durvalumab as a standard follow-up treatment to help keep limited-stage small cell lung cancer from returning after initial chemoradiation.
What could go wrong
This is a single-arm, open-label study with only 70 participants, so results may not apply broadly. Immunotherapy can cause immune-related side effects, and the drug may not improve outcomes for all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.